A5061220560- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Galectins and Cancer Biology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Virus-based gene therapy research
- Nanowire Synthesis and Applications
Siriraj Hospital
2021-2025
Mahidol University
2021-2025
Cholangiocarcinoma (CCA) is a lethal bile duct cancer that responds poorly to current standard treatments. A new therapeutic approach is, therefore, urgently needed. Adoptive T cell transfer using chimeric antigen receptor (CAR) cells modality with demonstrated efficacy in hematologic malignancies. However, its against solid tumors modest, and further intensive investigation continues. An important factor influences the success of CAR therapy selection target highly expressed on cells, but...
The treatment of breast cancer (BC) remains a formidable challenge due to the emergence drug resistance, necessitating exploration innovative strategies. Chimeric antigen receptor (CAR)-T cell therapy, groundbreaking approach in hematologic malignancies, is actively under investigation for its potential application solid tumors, including BC. Trophoblast surface 2 (Trop2) has emerged as promising immunotherapeutic target various cancers and notably overexpressed To enhance therapeutic...
Advanced cholangiocarcinoma (CCA) presents a clinical challenge due to limited treatment options, necessitating exploration of innovative therapeutic approaches. Bispecific T cell engager (BTE)-armed therapy shows promise in hematological and solid malignancies, offering potential advantages safety over continuous BTE infusion. In this context, we developed novel BTE, targeting CD3 on cells integrin αvβ6, an antigen elevated various epithelial cancer cells. The was generated by fusing...
Abstract Cholangiocarcinoma (CCA) is a fatal bile duct cancer with high resistance and recurrence rates, only one fifth of patients eligible for surgical treatment. The disease resists standard chemotherapy often relapses. Chimeric antigen receptor (CAR) T cell therapy has shown promise hematological malignancies but faces challenges in solid tumors due to mechanisms like PD-L1 expression, which use evade the immune system. To address this challenge, we developed fifth-generation CAR cells...
<title>Abstract</title> Cholangiocarcinoma (CCA) is a fatal bile duct cancer with high resistance and recurrence rates, only one fifth of patients eligible for surgical treatment. The disease resists standard chemotherapy often relapses. Chimeric antigen receptor (CAR) T cell therapy has shown promise hematological malignancies but faces challenges in solid tumors due to mechanisms like PD-L1 expression, which use evade the immune system. To address this challenge, we developed...